A data‐driven disease progression model of fluid biomarkers in genetic FTD

Media type: E-Article
Title: A data‐driven disease progression model of fluid biomarkers in genetic FTD
Contributor: van der Ende, Emma; Bron, Esther E.; Poos, Jackie M.; Jiskoot, Lize C.; Panman, Jessica L.; Papma, Janne M.; Wilke, Carlo; Synofzik, Matthis; Heller, Carolin; Swift, Imogen J.; Esteve, Aitana Sogorb; Bouzigues, Arabella; Borroni, Barbara; Sanchez‐Valle, Raquel; Moreno, Fermin; Graff, Caroline; Laforce, Robert; Galimberti, Daniela; Masellis, Mario; Tartaglia, Maria Carmela; Finger, Elizabeth; Vandenberghe, Rik; Rowe, James B.; Mendonca, Alexandre; [...]
imprint: Wiley, 2021
Published in: Alzheimer's & Dementia
Language: English
DOI: 10.1002/alz.053497
ISSN: 1552-5260; 1552-5279
Keywords: Psychiatry and Mental health ; Cellular and Molecular Neuroscience ; Geriatrics and Gerontology ; Neurology (clinical) ; Developmental Neuroscience ; Health Policy ; Epidemiology
Origination:
Footnote:
Description: <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Several fluid biomarkers for genetic frontotemporal dementia (FTD) have been proposed, including those reflecting neuroaxonal loss (neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain (pNfH)), synapse dysfunction (neuronal pentraxin 2 (NPTX2)), gliosis (glial fibrillary acidic protein (GFAP)) and complement activation (C3b, C1q). Determining the sequence in which biomarkers become abnormal over the course of disease could facilitate disease staging in FTD and enable us to identify mutation carriers with prodromal or early‐stage FTD, which is especially important as pharmaceutical interventions emerge. We aimed to model the sequence of biomarker abnormalities in presymptomatic and symptomatic genetic FTD using cross‐sectional data from the Genetic Frontotemporal dementia Initiative (GENFI).</jats:p></jats:sec><jats:sec><jats:title>Method</jats:title><jats:p>276 presymptomatic and 142 symptomatic carriers of mutations in <jats:italic>GRN, C9orf72</jats:italic> or <jats:italic>MAPT</jats:italic>, as well as 247 non‐carriers, were selected from the GENFI cohort based on availability of one or more of the aforementioned biomarkers. Nine presymptomatic carriers developed symptoms within 18 months of data collection (‘converters’). Sequences of biomarker abnormalities were modelled for the entire group using discriminative event‐based modelling (DEBM) and for each genetic subgroup using co‐initialized DEBM. These models estimate probabilistic biomarker abnormalities in a data‐driven way and do not rely on prior diagnostic information or biomarker cut‐off points. We estimated individual disease severity scores based on the position of subjects along the disease progression timeline through cross‐validation.</jats:p></jats:sec><jats:sec><jats:title>Result</jats:title><jats:p>Cerebrospinal fluid (CSF) NPTX2 was the first detectable abnormal biomarker, followed by blood and CSF NfL, blood GFAP, blood pNfH and finally CSF C1q and C3b (Fig. 1). Biomarker orderings did not differ significantly between genetic subgroups. Estimated disease severity scores (Fig. 2) could distinguish symptomatic from presymptomatic carriers and non‐carriers with areas under the curve (AUC) of 0.84 and 0.90 respectively. The AUC to distinguish converters from non‐converting presymptomatic carriers was 0.85.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>In our data‐driven disease progression models of genetic FTD, NPTX2 and NfL were the first biomarkers to become abnormal. Further research should focus on their utility as candidate selection tools for pharmaceutical trials. Estimating disease stages using DEBM could enable us to identify presymptomatic carriers approaching symptom onset and track the efficacy of therapeutic interventions.</jats:p></jats:sec>

Search in field:

Recently searched for: